The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS) is very high. A widely recognized bottleneck in the selection of promising central nervous system drug candidates from the development pipeline is the lack of sufficiently predictive animal models. Here, we review how the experimental autoimmune encephalomyelitis (EAE) model in the Neotropical primate "common marmoset" can help to bridge the gap between rodent EAE models and MS. The EAE model in the marmoset closely resembles MS in the clinical as well as pathological presentation and can be used for fundamental research into immunopathogenic mechanisms and for therapy development. We discuss recent insights arising from this model, both on...
The absence of pathological hallmarks of progressive multiple sclerosis (MS) in commonly used rodent...
The experimental autoimmune encephalitis (EAE) model is used for preclinical research into the patho...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...
New drugs often fail in the translation from the rodent experimental autoimmune encephalomyelitis (E...
The many, highly specific, biological therapies for immune-based diseases create a need for valid pr...
textabstractMultiple sclerosis (MS) is a major cause of disability in young adults affecting approxi...
The efficacy of many new immunomodulatory therapies for multiple sclerosis (MS) patients has often b...
Due to their genetic and immunological proximity to humans, the common marmoset, Callithrix jacchus,...
Despite years of intensive research into multiple sclerosis (MS) scientists have not yet succeeded i...
Introduction: The translation of scientific discoveries made in animal models into effective treatme...
Multiple sclerosis (MS) is one of the most intensively studied immune-based inflammatory diseases (I...
The increasing prevalence of chronic autoimmune-mediated inflammatory disorders (AIMIDs) in aging hu...
Aging Western societies are facing an increasing prevalence of chronic autoimmune-mediated inflammat...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...
The absence of pathological hallmarks of progressive multiple sclerosis (MS) in commonly used rodent...
The absence of pathological hallmarks of progressive multiple sclerosis (MS) in commonly used rodent...
The experimental autoimmune encephalitis (EAE) model is used for preclinical research into the patho...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...
New drugs often fail in the translation from the rodent experimental autoimmune encephalomyelitis (E...
The many, highly specific, biological therapies for immune-based diseases create a need for valid pr...
textabstractMultiple sclerosis (MS) is a major cause of disability in young adults affecting approxi...
The efficacy of many new immunomodulatory therapies for multiple sclerosis (MS) patients has often b...
Due to their genetic and immunological proximity to humans, the common marmoset, Callithrix jacchus,...
Despite years of intensive research into multiple sclerosis (MS) scientists have not yet succeeded i...
Introduction: The translation of scientific discoveries made in animal models into effective treatme...
Multiple sclerosis (MS) is one of the most intensively studied immune-based inflammatory diseases (I...
The increasing prevalence of chronic autoimmune-mediated inflammatory disorders (AIMIDs) in aging hu...
Aging Western societies are facing an increasing prevalence of chronic autoimmune-mediated inflammat...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...
The absence of pathological hallmarks of progressive multiple sclerosis (MS) in commonly used rodent...
The absence of pathological hallmarks of progressive multiple sclerosis (MS) in commonly used rodent...
The experimental autoimmune encephalitis (EAE) model is used for preclinical research into the patho...
The high failure rate of immunotherapies in multiple sclerosis (MS) clinical trials demonstrates pro...